Canyon Labs Acquires iuvo BioScience’s Laboratory and Consulting Divisions

• Canyon Labs has acquired iuvo BioScience’s laboratory services and scientific consulting divisions.

• This acquisition enables Canyon Labs to expand its end-to-end solutions for pharmaceutical and medical device development while iuvo BioScience continues its focus on ophthalmic clinical research.

Canyon Labs, a company that provides analytical and packaging lab testing for medical devices and pharmaceuticals, has announced the acquisition of iuvo BioScience’s laboratory services and scientific consulting divisions. This move strengthens both organisations’ market positions and provides Canyon Labs with expanded capabilities in pharmaceutical and medical device development.

The transaction, which integrates iuvo BioScience’s personnel into Canyon Labs’ operations, positions the company to deliver comprehensive, end-to-end solutions. As part of the deal, iuvo BioScience retains its clinical research team and leadership, maintaining its focus on ophthalmic clinical development services.

“This acquisition marks a significant milestone in the growth of Canyon Labs’ capacity and capabilities,” said Sarah (Rosenblum) Ptach, President of Canyon Labs. The integration of iuvo’s laboratory services enhances Canyon Labs’ service offerings, reducing lead times and increasing capacities in key areas such as sterility, biocompatibility testing, microbiology, and analytical chemistry. Canyon Labs now operates from three locations, including a new site in Rochester, NY.

Ben Burton, President and CEO of iuvo BioScience, commented on the deal, noting that the strategic acquisition allows iuvo to sharpen its focus on advancing its ophthalmic clinical research services, ultimately accelerating access to vision care treatments.

This acquisition follows iuvo BioScience’s purchase of Promedica International earlier in 2024, further bolstering its position as a leader in ophthalmic clinical research. Meanwhile, Canyon Labs’ strengthened capabilities align with its continued growth strategy, supported by its backing from MedVenture Health.